Floatz logo

Pimavanserin

Major Depressive Disorder

Icahn School of Medicine at Mount SinaiSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

197 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Risperidone
Johns Hopkins University
Phase 4BBB
Selegiline
Corium Innovations, Inc.
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB
Vortioxetine
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Pimavanserin is also rated in:

Lewy body dementiaActive
BB
Indicative · Phase 4
64 / 100
View asset →
neurodegenerative diseaseActive
BB
Indicative · Phase 4
64 / 100
View asset →
Parkinson diseaseActive
B
Indicative · Phase 4
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →